N/A N=46 Restrictive Fluid Therapy in Severe Preeclampsia
Pre-Eclampsia
Primary: Renal Function in Severe Preeclampsia With Restrictive Fluid Therapy — 0.69; 0.73; 0.99; 0.93 mg/dl — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=110 Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
Preeclampsia Severe
Primary: Number of Participants With the Change in Blood Pressure (Both Systolic and Diastolic) Under the Treatment of NIfedipine 30mg XL Versus Placebo — 18; 27 Participants
Early Phase 1 N=23 Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia
Preeclampsia
Primary: Microvascular Endothelial Function (Cutaneous Conductance, %Maximum) — 95; 77 % of maximal cutaneous conductance
Phase 3 N=65 Furosemide vs. Placebo for Severe Antepartum Hypertension
Pre-Eclampsia · Hypertension in Pregnancy · Pregnancy Complications
Primary: Mean Systolic Blood Pressure During Hour After Study Drug — 147; 152 mmHg
Phase 2 N=208 Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Phase 3 N=2,464 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention
Pregnancy Complications · Preeclampsia
Primary: Preeclampsia — 169; 156 Participants — p=0.37
N/A N=343 Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy
Hypertension, Pregnancy-Induced · Postpartum Preeclampsia · Hypertension; Maternal
Primary: Proportion of Participants With Recorded Blood Pressure Values in Office — 43; 44; 49; 56 Participants
N/A N=445 Platelet Count Trends in Pre-eclamptic Parturients
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Phase 3 N=10,154 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)
Preeclampsia
Primary: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate — 305; 285 Participants — p=0.42
Phase 4 N=100 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
Pre-Eclampsia · HELLP Syndrome · Eclampsia
Primary: Duration of Severe-range Hypertension After Delivery — 38.0; 35.3 hours — p=0.3
Phase 2 N=118 ToRsemide for pOstpartum HYpertension
Preeclampsia
Primary: Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg — 26; 34 Participants
Phase 3 N=400 Low Doses of Aspirin in the Prevention of Preeclampsia
Preeclampsia
Primary: Incidence of Preterm (<37 Weeks) Preeclampsia — 22; 16 Participants — p=0.28
N/A N=124 Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure
Preeclampsia · Hypertension
Primary: Nocturnal Blood Pressure — 128.2; 124.7; 70.6; 68.8 mmHg — p=0.45
N/A N=151 Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
Cardiovascular Disease · Preeclampsia · Hypertension
Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale
Phase 3 N=220 Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
Pre-Eclampsia · Hypertension in Pregnancy · Obesity
Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants
Early Phase 1 N=11 Losartan for Improved Vascular Endothelial Function After Preeclampsia
Preeclampsia Postpartum
Primary: Cutaneous Conductance (%Maximum) Response to Acetylcholine — 89.4; 72.5 % of maximal cutaneous conductance
Phase 2 N=23 Study of Nicotinamide in Early Onset Preeclampsia
Pre-Eclampsia · Pregnancy Related
Primary: Change in Mean Arterial Blood Pressure (MAP) — 0; 2; 4 mmHg
Phase 4 N=66 Magnesium Sulfate in Obese Preeclamptics
Preeclampsia
Primary: Maternal Serum Magnesium Level at 4 Hours After Administration — 3.53; 4.41 mg/dL
N/A N=186 Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia
Pre-eclampsia
Primary: Detection of Fluid in the Lungs — 2; 3 Participants — p=.162
Phase 1 N=10 Phase I Study of Nicotinamide for Early Onset Preeclampsia
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Phase 4 N=2,408 Chronic Hypertension and Pregnancy (CHAP) Project
Hypertension
Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001
N/A N=110 Phenylephrine in Spinal Anesthesia in Preeclamptic Patients
Preeclampsia · Hypotension
Primary: The Umbilical Artery pH — 7.22; 7.20 pH — p=.38
Phase 2 N=384 Furosemide for Accelerated Recovery of Blood Pressure Postpartum
Hypertension, Pregnancy-Induced
Primary: Persistently Elevated Blood Pressures 7 Days Postpartum — 10; 23 Participants — p=0.03
Phase 2 N=51 Efficacy Study of Digibind for Treatment of Severe Preeclampsia
Pre-eclampsia
Primary: Change in Creatinine Clearance — -8; -22 milliliters/minute
Phase 4 N=109 Response to Anti-hypertensives in Pregnant and Postpartum Patients
Hypertension in Pregnancy · Preeclampsia
Primary: Time to Achieve Non Severe Range Blood Pressure — 10; 20 minutes
N/A N=202 Hypertension In Postpartum Preeclampsia Study
Hypertension, Pregnancy-Induced
Primary: Average Mean Arterial Blood Pressure- Mild Group — 93; 93 mmHg
Phase 3 N=82 Lasix for the Prevention of De Novo Postpartum Hypertension
Postpartum Pregnancy-Induced Hypertension · Postpartum Preeclampsia · Hypertension, Pregnancy-Induced
Primary: Mean Arterial Blood Pressure (MAP) — 88.9; 86.8 mmHg
Phase 4 N=43 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
Hypertension, Pregnancy-Induced · Pre-eclampsia
Primary: Difference in Systolic Blood Pressure (SBP) — 131.8; 132.0; 129.1; 129.1 mmHg
N/A N=47 Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
Preeclampsia With Severe Features
Primary: Duration of Magnesium Sulfate Use in the Postpartum Period Defined as the Duration in Hours Between Delivery and Discontinuation of Magnesium Sulfate. — 21.6; 24 hours
Phase 3 N=120 Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Preeclampsia
Primary: Increase in Gestational Age in Days — 5.0; 6.0 days